公开(公告)号：US20060223741A1

公开(公告)日：2006-10-05

申请号：US11315354

申请日：2005-12-23

申请人： Maree Smith ,  Bruce Wyse

发明人： Maree Smith ,  Bruce Wyse

IPC分类号： A61K38/17 ,  A61K48/00 ,  A61K31/503 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/4709

CPC分类号： C07D471/04 ,  A61K31/517 ,  A61K38/08 ,  C07D239/90 ,  C07D401/06 ,  C07D403/10 ,  C07D403/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/12 ,  G01N33/74 ,  G01N2500/00

摘要： The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects. The AT2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of neuropathic conditions.

摘要翻译： 本发明涉及可用于预防和改善与神经病变相关的体征和症状的方法和试剂。 更具体地，本发明公开了血管紧张素II受体2（AT2受体）拮抗剂用于神经性疼痛的治疗，预防，逆转和/或症状缓解的用途，包括机械痛觉过敏，热或机械 异常性疼痛，糖尿病疼痛和包埋疼痛，在脊椎动物中，特别是在人类受试者中。 AT 2受体拮抗剂可以单独提供或与其它化合物组合提供，例如可用于控制神经病症状况的那些。

公开(公告)号：US20090291975A1

公开(公告)日：2009-11-26

申请号：US12469438

申请日：2009-05-20

申请人： WARREN STERN ,  Gary W. Pace ,  Felix A. de la IgLesia ,  Maree Smith ,  Patricia Richards

发明人： WARREN STERN ,  Gary W. Pace ,  Felix A. de la IgLesia ,  Maree Smith ,  Patricia Richards

IPC分类号： A61K31/485 ,  A61P29/00

CPC分类号： A61K31/485 ,  A61K9/0095 ,  A61K2300/00

摘要： Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with optimal ratios of morphine and oxycodone that provide superior analgesic efficacy and lower incidence of adverse side effects compared to morphine and oxycodone alone. The pharmaceutical compositions comprise morphine and oxycodone, or pharmaceutically acceptable salts thereof, in ratios of about 3 to 2 to about 1 to 2, morphine to oxycodone by weight.

摘要翻译： 提供了与吗啡和羟考酮相比，吗啡和羟考酮的最佳比例减轻疼痛的药物组合物和方法，其提供优异的止痛效力和较低的与吗啡和羟考酮相比的不利副作用的发生率。 药物组合物包含约3至2至约1至2的吗啡和羟考酮或其药学上可接受的盐，吗啡与羟考酮的重量比。

公开(公告)号：US20070031489A1

公开(公告)日：2007-02-08

申请号：US11544187

申请日：2006-10-06

申请人： Gary Pace ,  Maree Smith

发明人： Gary Pace ,  Maree Smith

IPC分类号： A61K31/485 ,  A61K31/445 ,  A61K9/20

CPC分类号： A61K45/06 ,  A61K31/445 ,  A61K31/485 ,  A61K2300/00

摘要： The present invention relates to methods for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed with respiratory illness by administering an analgesic composition comprising a sub-analgesic dosage of a p-opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone which is a κ2-opioid agonist or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明涉及通过施用镇痛组合物来降低与诊断或未诊断为呼吸系统疾病的患者中的阿片样镇痛药相关的风险的方法，所述止痛组合物包含选自吗啡的对 - 阿片样物质激动剂的次镇痛剂量， 芬太尼，舒芬太尼，阿芬太尼，羟吗啡酮和氢吗啡酮，或其药学上可接受的盐，以及作为κ2-阿片样物质激动剂或其药学上可接受的盐的羟考酮的次镇痛剂量。

公开(公告)号：US20050053659A1

公开(公告)日：2005-03-10

申请号：US10661458

申请日：2003-09-10

申请人： Gary Pace ,  Maree Smith

发明人： Gary Pace ,  Maree Smith

IPC分类号： A61K9/22 ,  A61K31/445 ,  A61K31/485 ,  A61K45/06 ,  A61P11/00 ,  A61P25/04

CPC分类号： A61K45/06 ,  A61K31/445 ,  A61K31/485 ,  A61K2300/00

摘要： The present invention relates to methods for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed with respiratory illness by administering an analgesic composition comprising a sub-analgesic dosage of a μ-opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone which is a κ2-opioid agonist or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明涉及通过施用镇痛组合物来降低与诊断或未诊断呼吸系统疾病的患者中阿片样镇痛药相关的风险的方法，所述镇痛组合物包含选自以下的阿片样物质激动剂：吗啡， 芬太尼，舒芬太尼，阿芬太尼，羟吗啡酮和氢吗啡酮，或其药学上可接受的盐，以及作为κ-阿片样物质激动剂或其药学上可接受的盐的羟考酮的次镇痛剂量。

公开(公告)号：US06310072B1

公开(公告)日：2001-10-30

申请号：US08921187

申请日：1997-08-29

申请人： Maree Smith ,  Fraser Ross

发明人： Maree Smith ,  Fraser Ross

IPC分类号： A61K31485

CPC分类号： A61K45/06 ,  A61K31/445 ,  A61K31/485

摘要： An analgesic composition is disclosed comprising a sub-analgesic dosage of a &mgr;-opioid agonist, optionally in the form of a pharmaceutically acceptable salt, and a sub-analgesic dosage of a &kgr;2-opioid agonist, optionally in the form of a pharmaceutically acceptable salt. There is also disclosed a method for producing analgesia in humans and lower animals which comprises administering concurrently to a human or lower animal in need of such treatment an analgesic composition of the invention.

摘要翻译： 公开了镇痛组合物，其包含任选呈药物可接受的盐形式的μ-阿片样物质激动剂的次镇痛剂量和任选呈药学上可接受的盐形式的κ-阿片样物质激动剂的次镇痛剂量 。 还公开了一种在人类和低等动物中产生止痛的方法，其包括同时施用本发明的止痛组合物的需要这种治疗的人或低级动物。